Edwards Lifesciences Corporation filings document regulatory disclosures for a Delaware medical technology company with common stock listed on the New York Stock Exchange under EW. Recent Form 8-K reports furnish quarterly and annual operating results, including sales commentary tied to transcatheter aortic valve replacement and transcatheter mitral and tricuspid therapies.
Proxy and material-event filings cover board elections, executive compensation, shareholder voting results, amendments to the Long-Term Stock Incentive Compensation Program, and senior finance leadership changes. These records also identify the company’s registered common stock structure and formal governance matters submitted to stockholders.
Edwards Lifesciences (EW) reported insider activity by its Chief Financial Officer. On 11/10/2025, the officer exercised employee stock options for 13,000 shares of common stock at an exercise price of $59.2567 per share and executed sales on the same date pursuant to a Rule 10b5-1 trading plan adopted on July 29, 2025.
The transactions included two sales: 2,974 shares at a weighted average price of $83.2999 (trades ranged from $83.270 to $83.415) and 10,026 shares at a weighted average price of $83.0201 (trades ranged from $82.270 to $83.260). Following these transactions, direct beneficial ownership stood at 39,898 shares, with an additional 266,318 shares held indirectly by trust. After the option exercise, 46,700 derivative securities (stock options) remained beneficially owned.
Edwards Lifesciences (EW) reported an insider Form 4 for an officer (CVP, JAPAC) on 11/10/2025. The reporting person exercised 1,020 employee stock options at $59.2567 and sold 1,020 common shares at a weighted average price of $82.5451, with trades ranging from $82.27 to $82.90. These transactions were made under a Rule 10b5-1 trading plan adopted on July 30, 2025. After the transactions, direct ownership was 22,001.9103 shares, and 6,114 derivative securities remained held directly.
Edwards Lifesciences (EW) filed a Form 144 for a proposed sale of 3,058 shares of common stock through Charles Schwab & Co., Inc. on 11/10/2025. The aggregate market value listed is $252,423, with sales on the NYSE. The shares were acquired the same day via an employee stock option exercise with broker payment for a cashless exercise. Shares outstanding were 580,300,000; this is a baseline figure, not the amount being sold.
Edwards Lifesciences (EW) reported a planned sale under Form 144. The notice covers up to 20,700 common shares with an aggregate market value of $1,719,841.00, to be executed through Charles Schwab on or about 11/10/2025 on the NYSE. The seller acquired the shares via an employee stock option exercise with a broker payment for cashless exercise on the same date. Shares outstanding were 580,300,000 at the time cited.
Edwards Lifesciences (EW) reported Q3 2025 results. Net sales rose to $1,553.1M from $1,354.4M, while operating income declined to $307.1M from $350.6M as expenses increased. Diluted EPS from continuing operations was $0.50 versus $0.61 a year ago. Total diluted EPS was $0.50, compared with $5.13 last year, which included a large discontinued operations gain.
The quarter included $90.4M of certain litigation expenses and a $40.0M intangible asset impairment, partially offset by a $12.5M favorable change in contingent consideration and $12.5M of other operating income. Year-to-date cash from operations improved to $1,144.3M. Cash, cash equivalents, and restricted cash were $2,694.8M at period end.
Following the 2024 sale of Critical Care, discontinued operations posted a small loss this quarter. Edwards recorded TSA income of $12.7M and reported a remaining unfavorable contract liability of $47.1M tied to services, with a net payable to BD of approximately $84.4M. The company repurchased $852.8M of stock year-to-date and acquired the remaining interest in Vectorious for $233.7M. Shares outstanding were 580.3 million as of October 31, 2025.
Edwards Lifesciences announced a planned leadership change as Chief Financial Officer Scott Ullem informed the company he will transition from his role by mid-year 2026.
The company has begun a selection process to appoint a new CFO. A press release announcing the transition plan was issued on October 30, 2025 and furnished under Item 7.01; it is not deemed “filed” under the Exchange Act.
Edwards Lifesciences (EW) furnished a press release announcing its financial results for the third quarter of 2025. The disclosure was made via Form 8-K under Item 2.02.
The press release is included as Exhibit 99.1 and the information is being furnished, not deemed filed, under the Exchange Act.
BlackRock, Inc. filed a Schedule 13G/A reporting beneficial ownership of 44,267,376 shares (7.5%) of Edwards Lifesciences common stock as of 09/30/2025.
BlackRock reports sole voting power over 40,035,206 shares and sole dispositive power over 44,267,376 shares, with no shared voting or dispositive power. The filer is classified as a HC (parent holding company) and certifies the securities were acquired and are held in the ordinary course, not for the purpose of changing or influencing control.
Edwards Lifesciences (EW) reported a Form 144 notice indicating that Larry L. Wood plans to sell 8,950 shares of common stock. The filing lists an aggregate market value of 653,522.00 and an approximate sale date of 10/16/2025. The broker is Charles Schwab & Co., Inc., and the shares are listed on the NYSE.
The shares to be sold were acquired on 10/16/2025 through an employee stock option exercise via a broker payment for cashless exercise. The filing also notes a prior sale in the past three months: 8,950 shares on 08/18/2025 for gross proceeds of 698,679.00. Shares outstanding are listed as 587,100,000; this is a baseline figure, not the amount being sold.
Andrew M. Dahl, SVP and Corporate Controller of Edwards Lifesciences (EW), reported a sale of 262 shares of common stock on 09/13/2025 at a price of $77.57 per share. After the reported transaction, the filing shows beneficial ownership of 7,926.9331 shares. The form notes this filing reflects changes in beneficial ownership only and includes a quarterly acquisition under the issuer's Employee Stock Purchase Plan.